Status:
WITHDRAWN
Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients
Lead Sponsor:
Sadat City University
Conditions:
COVID
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
PHASE2
Brief Summary
With potential antiviral effects on severe acute respiratory syndrome (SARS) and as a methyl-xanthine derived inhibitor of phosphodiesterase-4, pentoxifylline basically functions as a hemorrheologic a...
Eligibility Criteria
Inclusion
- Positive COVID-19 test
- Age \>/= 18 y.o.
Exclusion
- Allergic reaction to Pentoxifylline
- Ongoing anticoagulation
- History of GI bleeding
- History of Seizures
- Cardiac or other vascular stents
- History of severe renal disease
- History of intracranial hemorrhage.
Key Trial Info
Start Date :
November 13 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04433988
Start Date
November 13 2022
End Date
December 30 2022
Last Update
January 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine
Shibīn al Kawm, Egypt